Spots Global Cancer Trial Database for A Bioequivalence Study of Dasatinib Tablet
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Bioequivalence Study of Dasatinib Tablet
Official Title: A Bioequivalence Study Between the Generic Dasatinib Tablet and Reference Product in Vivo
Study ID: NCT05640804
Conditions
Study Description
Brief Summary: This is a clinical study to evaluate the bioequivalence of dasatinib tablet produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Sprycel® produced by Bristol Myers Squibb after single dose in healthy subjects, so as to provide reference for clinical evaluation and clinical medication; to observe the safety of the dasatinib tablet and the reference drug Sprycel® in healthy subjects under fasting and fed states.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
